Agomab Therapeutics

Update in progress

AGMB (NasdaqGS)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, with a focus on chronic fibrotic conditions. Its pipeline includes Ontunisertib (AGMB-129), an oral, gut-restricted ALK5/TGFßR1 inhibitor for Fibrostenosing Crohn’s disease in Phase 2a; AGMB-447, an inhaled ALK5/TGFßR1 inhibitor for idiopathic pulmonary fibrosis in Phase 1; and AGMB-101, a HGF-mimetic antibody that stimulates the MET receptor with antifibrotic activity in preclinical models. Incorporated 2017, based in Antwerp, Belgium.